Search

Your search keyword '"Blanco, Julià"' showing total 507 results

Search Constraints

Start Over You searched for: Author "Blanco, Julià" Remove constraint Author: "Blanco, Julià" Language english Remove constraint Language: english
507 results on '"Blanco, Julià"'

Search Results

1. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

2. Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

3. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity

4. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

6. Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

7. An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

11. β-Cyclodextrins as affordable antivirals to treat coronavirus infection

12. Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

13. Macrophage CD5L is a target for cancer immunotherapy

14. Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

15. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

16. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

19. Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients

20. Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission

21. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

22. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

23. Detection of SARS-CoV-2 in a cat owned by a COVID-19–affected patient in Spain

24. SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

25. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

26. Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein.

27. Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells

28. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

29. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

32. Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

36. Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection

42. Evolution of the gut microbiome following acute HIV-1 infection

43. HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic

44. Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration.

45. Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

47. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

Catalog

Books, media, physical & digital resources